In the era of digital health transformation, generative AI (GenAI) has emerged as a breakthrough technology in pharmacovigilance, the science dedicated to ensuring drug safety.
Pharma companies are moving their Generative AI (GenAI) investments from pilot to production through exploration, experimentation, industrialisation/scaling, adoption, and monetisation.
Generative AI (GenAI) technology is already transforming everyday regulatory and safety processes, thanks to its ability to digest, assess, and summarise key insights and findings from acro
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year